We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $165K invested in Array Biopharma Inc in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more capital invested

Capital invested by funds: $86.3K → $165K (+$78.7K)

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CWM
CIBC World Markets
New York
+$95.4K

Top Sellers

No sellers this quarter

ARRY Hedge Fund Activity: Q1 2025 in Review

1 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2025, worth a combined $165K — up 91% from $86.3K a quarter earlier.

Fund positioning in ARRY was balanced in Q1 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was CIBC World Markets, adding an estimated $95.4K.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $165K of Array Biopharma Inc stock for Q1 2025, up 91% quarter-over-quarter.
  • 0 funds opened new Array Biopharma Inc positions in Q1 2025 and 0 closed out.
  • The largest Array Biopharma Inc buyer in Q1 2025 was CIBC World Markets, an estimated $95.4K added.

Based on aggregated 13F filings for Q1 2025.